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Abstract
Background: Analyses of adverse events (AEs) are an important aspect of benefit-
risk and health-technology assessments of therapies. The SAVVY (Survival analysis
for AdVerse events with Varying follow-up times) project aims to improve the analyses
of AE data in clinical trials through the use of survival techniques appropriately deal-
ing with varying follow-up times and competing events (CEs). In an empirical study
including randomized clinical trials (RCT) from several sponsor organisations the ef-
fect of varying follow-up times and competing events on comparisons of two treatment
arms with respect to AE risks is investigated.
Methods: CEs definition does not only include death before AE but also end of
follow-up for AEs due to events possibly related to the disease course or safety of the
treatment. The comparisons of relative risks (RRs) of standard probability-based es-
timators to the gold-standard Aalen-Johansen estimator or hazard-based estimators
to an estimated hazard ratio (HR) from Cox regression are done descriptively, with
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graphical displays, and using a random effects meta-analysis on AE level. The influ-
ence of different factors on the size of the bias is investigated in a meta-regression.
Results: Ten sponsors provided seventeen RCTs including 186 types of investigated
AEs. We find that decisions on categorizing the size of the effect based on RRs of AE
probabilities according to guidelines issued by the German Institute for Quality and
Efficiency in Health Care (IQWiG) crucially depend on the estimator chosen. We con-
firm for estimation of the RR concerns regarding incidence densities: the probability
transform incidence density ignoring CEs performed worst. However, accounting for
CEs in an analysis that parametrically mimicked the non-parametric Aalen-Johansen
performed better than both one minus Kaplan-Meier and Aalen-Johansen that only
considered death as a CE. In terms of relevance of effects, the choice of the estimator is
key and more important than the features of the underlying data such as percentage of
censoring, CEs, amount of follow-up, or value of the gold-standard RR. The analysis
based on hazards revealed that the incidence density underestimates the HR of AE
and CE of death hazard compared to the gold-standard Cox regression.
Conclusions: Both the choice of the estimator of the cumulative AE probability and
a careful definition of CEs are crucial in estimation of RRs. Categorization of evi-
dence crucially depends on the chosen estimator. There is an urgent need to improve
the guidelines of reporting AEs so that the Kaplan-Meier estimator and the incidence
proportion are finally replaced by the Aalen-Johansen estimator with appropriate def-
inition of CEs. For RRs based on hazards, the HR based on Cox regression has better
properties than the ratio of incidence densities.
Keywords: Aalen-Johansen estimator, Adverse Events, Competing Events, Drug
Safety, Risk-benefit assessment, Health-technology assessment, Incidence Proportion, In-
cidence Density, Kaplan-Meier estimator, Randomized Clinical Trial
1 Background
This paper reports findings of a methodological, empirical study of the SAVVY project
group when comparing safety in terms of AEs between treatment arms. The motivation is
that commonly employed methods to quantify absolute AE risk either do not account for
varying follow-up times or for CEs and may be grouped into methods that either under- or
overestimate cumulative AE probabilities in a time-to-first-event context. These concerns
have been thoroughly investigated in a companion paper[1], considering only one trial arm
in an opportunistic set of 186 types of AEs from seventeen RCTs from different disease
indications. Here, we extend these considerations to comparing AE risk between arms, the
challenge being that, say, the fact of overestimation in both arms of the same trial allows
for both under- and overestimation of RRs when comparing arms.
The SAVVY project group is a collaborative effort from academia and pharmaceutical
industry with the aim to improve the analyses of AE data in clinical trials through the use
of survival techniques that account for both varying follow-up times, censoring and CEs.
To this end, the companion paper has verified the relevance of using the Aalen-Johansen
estimator[2] as the non-parametric gold-standard method when quantifying absolute AE
risk. The reason is that the Aalen-Johansen estimator is the only (non-parametric) esti-
mator that accounts for CEs, censoring, and varying follow-up times simultaneously, and,
being non-parametric, does not rely on restrictive parametric assumptions such as incidence
densities do.
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Briefly, in the companion paper we found that the one minus Kaplan-Meier estimator
with simple censoring of CEs overestimates the cumulative AE probability. This is well-
known and has been shown either empirically, see Schuster et al.[3] for a recent example in
one single study, or analytically[4]. This paper builds on these and the one-sample results
analyzed in the companion paper Stegherr et al.[1] as follows: First, we consider the same
six estimators of AE probabilities as in Stegherr et al.[1] Second, we then extend the results
on the bias of estimation of absolute AE probabilities in one sample when compared to the
gold-standard Aalen-Johansen estimator to an assessment of how these same estimators
perform when estimating RRs between two randomized treatment arms. With this, we
answer a question raised in Unkel et al.[5], namely which direction the bias goes for an
estimator of a RR when based on biased one-sample estimators. Third, since in applications
very often the RR for AEs is not (only) quantified via estimates of AE probabilities but
also using an estimate of the HR of AE hazards, we extend the analysis to two hazard-
based estimators of RR. Here, on the one hand, we investigate to which extent incidence
densities may be used to approximate HR estimates from a semi-parametric Cox model.
On the other hand, we investigate the relevance of CEs and their CE-specific hazards by
investigating conclusions either based on a Cox model for time to AEs or based on a RR
for a probability using the Aalen-Johansen estimator. Properties and estimands of various
estimators to quantify RRs between two randomized arms, and when to prefer which, are
discussed elsewhere[5, 6]. And finally, our analysis is based on 186 types of AEs from
seventeen RCTs from several disease indications.
Individual trial data analyses were run within the sponsor organisation using SAS and
R software provided by the academic project group members. Only aggregated data neces-
sary for meta-analyses were shared and meta-analyses were run centrally at the academic
institutions.
2 Methods
Arm E is referring to the experimental treatment and Arm C to the control.
Since for a time-to-event endpoint, both AE probabilities and the amount of censoring
[7] are time-dependent, we will consider different evaluation times called τ . These evalua-
tion times either imposed no restriction, i.e., evaluated the estimators until the maximum
follow-up time (τE and τC in each arm, respectively), or considered the minimum of quan-
tiles of observed times in the two treatment arms; the quantiles were 100% (whose minimum
over both arms we denote by τmax = min{τE , τC}), 90%, 60% and 30%. For computation
of RRs for AE probabilities, in this paper we always use the same follow-up time in both
arms, i.e. τmax. The rationale to evaluate estimators at the latest meaningful time is that
this reflects common practice for the estimation of AE risk using the incidence proportion,
where simply the number of patients with a certain AE in a given time interval is divided
through the total number of patients. Analyses for maximum follow-up (which may be
arm-specific) were not performed. For hazard-based estimators we use all available data
and exclusively look at the arm-specific maximum follow-up time, i.e. τE and τC , also
when comparing arms. The partial likelihood estimator of the HR based on Cox regres-
sion “self-adjusts” for τmax in that it only requires data up this time point. To limit the
variability of the Cox HR we limit the considered dataset to those AEs with a frequency
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of ≥ 10 in each arm for hazard-based analyses.
2.1 Estimators of AE probabilities
As one-sample estimators of the AE probability we use the incidence proportion, the proba-
bility transform incidence density ignoring and accounting for CE, one minus Kaplan-Meier,
and the Aalen-Johansen estimator. A brief summary of one-sample estimators is given in
the companion paper[1]. An even more detailed Statistical Analysis Plan is presented
elsewhere [6].
2.2 Hazard-based analyses
For a time-to-event endpoint, the incidence density estimates the hazard function assum-
ing that it is constant[6, 1]. Their ratio therefore estimates a HR under the restrictive
assumption that the hazard functions of both treatment arms are constant. The common
Cox model is a semi-parametric extension which only requires the HR to be constant, but
not the hazards in the arms.
If we consider a time-to-event endpoint with just one possible event, e.g. death for
overall survival, then one minus the survival function, i.e. the expected proportion of
patients with the event of interest over time, bears a direct relationship to the (cumulative)
hazard. However, once we have to consider CEs, the direct relation between the hazard for
a given event and the cumulative incidence function, which takes the role of one minus the
survival (or “event-probability”) function, breaks down[8]. As a consequence, if we want
to use a hazard-based analysis to quantify the effect of treatment on the event of interest
and all CEs, in theory it is necessary to report all event-specific hazards, or rather the
corresponding HRs. For this reason, we will not only report the performance of hazard-
based RR estimators for the endpoint of interest, time to (first) AE, but also for the
competing endpoints time to a CE of death and time to all CEs (see “Definition of CEs” in
Stegherr et al.[1] and section below). This is in perfect analogy to not only consider a (one
minus Kaplan-Meier-like) simple probability transformation of the AE incidence density,
but to also consider an (Aalen-Johansen-like) transformation accounting for CEs.
2.3 Effect measures
For given estimators qˆE and qˆC of AE probabilities calculated at a specific evaluation time
within each treatment arm, one can consider either the risk difference, R̂D = qˆE − qˆC , the
RR, R̂R = qˆE/qˆC , or the odds ratio, ÔR = qˆE/(1− qˆE)/(qˆC/(1− qˆC)). In this paper, we
will focus on the RR to quantify the treatment effect. The IQWiG summarizes reasons
to prefer the RR over the risk difference in Appendix A[9] of their general methods. The
key feature therein that leads us to prefer the RR is that the risk difference is an absolute
effect measure and as such strongly depends on the baseline risk in the control arm.
Finally, we prefer the RR over the OR because it is easier to interpret in the sense
that it is an immediate comparison of the cumulative AE probabilities estimated in the
one-sample case[1].
Variance estimators are easily obtained via the delta rule. In the one-sample case,
estimates of AE probabilities were benchmarked on the gold-standard Aalen-Johansen
estimator with the primary definition of CEs, i.e. considering all clinical events described
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below as CEs. This, because the latter is a fully nonparametric estimator that accounts for
censoring, does not rely on a constant hazard assumption, and accounts for CEs, see Table 1
in Stegherr et al.[1]. Furthermore, as is well-known, simply taking one minus Kaplan-Meier
for time-to-first-AE is a biased estimator of the AE probability in presence of CEs. Here,
as a straightforward extension for the comparison of AE probabilities between two arms
using the RR, we benchmark the latter on the RR estimated using the Aalen-Johansen
estimator in each arm.
The gold-standard for estimates of the HR will be the HR from Cox regression. This,
because the latter is typically used to quantify a treatment effect not only for efficacy, but
also for time-to-first-AE type endpoints. Variances of comparisons of different estimators of
the HR will be received via bootstrapping[4]. The reason to bootstrap is that we compare
different estimators of the same quantity based on one data set, leading to the different
estimators being dependent.
As we base our analyses on real datasets we do not know the underlying true effects,
either RRs or HRs. This is why we chose the above gold-standard estimators to benchmark
the candidate estimators against. In what follows, we will still call the deviation of an
estimator under consideration to its respective gold-standard bias, although, of course,
the comparison is between estimators. We note however that, say, a comparison of one
minus Kaplan-Meier and Aalen-Johansen will converge in probability towards the true or
asymptotic bias when sample size tends to infinity.
2.4 Definition of CEs
The definition of events as CE (or “competing risk”) is discussed in detail in the companion
paper[1]. Briefly, both death before AE and any event that would both be viewed from a
patient perspective as an event of his/her course of disease or treatment and would stop
the recording of the AE of interest will be viewed as a CE, including possibly disease- or
safety-related loss to follow-up, withdrawal of consent, and discontinuation. The latter is
our primary definition of a CE while we will also look at a CE of “death only”. Even
though interpretation depends on the severity of the event, a categorization into these two
types of CEs is considered here for illustrative purposes. One motivation is that, in a time-
to-first-event analysis, the incidence proportion, that is, the number of AEs divided by
arm size, should be unbiased in the absence of censoring. To investigate the impact of our
primary CE definition, we also included an investigation of an estimator Aalen-Johansen
(death only), which only treated death before AE as competing, but not the other CEs
that belong to our primary definition.
An overview how the different estimators account for the three sources of bias, i.e.,
censoring, no constant hazards, and CEs is given in Table 1 in Stegherr et al.[1].
To explicitly investigate the role of censoring without the methodological complication
of CEs, a composite endpoint where AEs and CEs are combined into one single event is
considered. As a consequence, the gold-standard in this setting is the one minus Kaplan-
Meier estimator which is compared to the incidence proportion.
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2.5 Random effects meta-analysis and meta-regression
In the meta-analysis and meta-regression, the ratios of the RR estimates, either based on
probability or hazard estimates, obtained with one of the other estimators divided by the
RR estimate obtained with the gold-standard Aalen-Johansen estimator (for probabilities)
or the Cox regression HR (for hazard based) are considered on the log-scale. The standard
errors of these log-ratios are calculated with a bootstrap. Then, a normal-normal hierar-
chical model is fitted and the exponential of the resulting estimate can be interpreted as
the average ratio of the two RR estimators.
In a meta-regression it is further investigated which variables impact this average ratio.
Therefore, the proportion of censoring, the proportion of CEs, the evaluation time point
τ in years, and the size of the RR under consideration estimated by the gold-standard
are included as covariates in an univariable and a multivariable meta-regression. For the
latter, since the sum of the proportion of censoring, the proportion of CEs, and the value
of the gold-standard Aalen-Johansen estimator converge to 1, including all of them in the
model would lead to collinearity. For that reason, we omit the proportion of CEs in the
model. All covariates are centered in the meta-regressions.
2.6 RR categories
The impact of the use of the different estimators on the conclusions derived from the
comparison of treatment arms is investigated by the use of categories. These are typically
derived from comparing the confidence interval (CI) of the RR to thresholds. There is no
universally accepted standard how one should combine a point estimate and its associated
variability, in our case RR, into evidence categories. As an example, we use a categorization
motivated by the methods put forward by the IQWiG[9] for severe AEs (Table 14) to be
used for the German benefit-risk assessment. In contrast to the usual IQWiG procedure,
however, we do not only categorize the benefit of a therapy, but also the harm. Thereby,
in this first analysis we do not distinguish between a positive and a negative treatment
effect. Four categories are possible: (0) “no effect” if 1 is included in the CI, (a) “minor”
(“gering”) if the upper bound of the CI is in the interval [0.9, 1) for a RR< 1 or the
lower bound in the interval (1, 1.11] for a RR> 1, (b) “considerable” (“betra¨chtlich”) if
the upper bound of the CI is in the interval [0.75, 0.9) for a RR< 1 or the lower bound in
the interval (1.11, 1.33] for a RR> 1, and (c) “major” (“erheblich”) if the upper bound is
smaller than 0.75 for a RR< 1 or the lower bound greater than 1.33 for a RR> 1. The
same categorization is used for the HR instead of RR.
3 Results
3.1 Description of data
Ten organizations provided 17 trials including 186 types of AEs (median 8; interquartile
range [3; 9]). Twelve (71.6% out of 17) trials were from oncology, nine (52.9%) were actively
controlled and eight (47.1%) were placebo controlled. Median follow-up was 927 days in
Arm E (interquartile range [449; 1380]), 896 days in Arm C (interquartile range [308;
1263]), and 856 days (interquartile range [308; 1234]) in both arms combined. The trials
included between 200 and 7171 patients (median: 443; interquartile range [411; 1134]). In
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Figure 1: Relative frequency of observed events, per treatment arm.
Arm E, estimated values from the Aalen-Johansen estimator ranged from 0 to 0.95 with a
median of 0.09; in Arm C the range was from 0 to 0.77 with a median of 0.05. RRs based
on these estimates ranged from 0.28 to 16.81 with a median of 1.71. HRs for AE hazards
(restricted to AEs with ≥ 10 events in each arm) ranged from 0.14 to 10.83, with a median
of 1.30.
Figure 1 displays for the 186 types of AEs boxplots of the treatment-arm specific
observed relative frequencies, i.e., the number of a specific type of event divided by the
total number of patients. Events considered are “observed AE”, “observed death before
AE”, “observed other CEs” (i.e. excluding death), and “observed censoring”. Within each
arm, the figure illustrates a smaller amount of observed censoring compared to observed
CEs. That is, AE recording often ended due to death or other CEs such as treatment
discontinuation, preventing censoring of the time to AE. Comparing the arms we observe
more AEs in the treatment Arm E, a comparable number of deaths, and more CEs in the
control Arm C. All combined, this leads to less censoring in the control Arm C.
3.2 Impact on RR categories and decisions based on probability-based
relative AE risk estimates
In this paragraph we summarize a key finding of this paper: namely, that categorization
of evidence based on RR crucially depends on the estimator one uses to estimate the RR.
Table 1 shows the evidence categories for our considered estimators of the RR of those AEs
where neither the estimated AE probability in Arm E nor the estimated AE probability in
Arm C is 0 (n = 155 types of AEs for one minus Kaplan-Meier and n = 156 types of AEs
for all other estimators).
Overall, we find quite a number of switches to neighboring categories. Reasons for
switches are wider CIs of the Aalen-Johansen estimator as well as RR estimates / CI
bounds that are close to the cutoffs between categories. As the incidence proportion on
average estimates the RR well (third column in Table 2), we see a similar number of switches
to a higher (n = 8, below the diagonal in Table 1) and lower (n = 9) evidence category.
Interestingly, while on average the probability transform of the incidence density accounting
for CEs is approximately unbiased as well, we see double as many effect upgradings (n =
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Table 1: The impact of the choice of relative effect estimator for AE probabilities on qualitative
conclusions. Diagonal entries are set in bold face. Deviations from the gold-standard Aalen-
Johansen estimator are the off-diagonal entries. Off-diagonal zeros are omitted from the display.
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14) as downgradings (n = 7). Quite logically, for those estimators that underestimate
the RR with respect to the gold-standard Aalen-Johansen estimator, namely probability
transform incidence density ignoring CEs, one minus Kaplan-Meier, and Aalen-Johansen
(death only) we see relevantly more switches to a lower than higher evidence category,
namely n = 41/n = 16, 32/8, and 28/6, respectively.
Switches between categories are more rare for a given estimator for earlier follow-up
times, mainly because of increased variability (results not shown).
In summary, the choice of the estimator of the RR does have an impact on the conclu-
sions.
In what follows, we will describe the different properties of the considered estimators
that ultimately lead to this relevant number of diverging conclusions.
3.3 Estimators of AE probabilities compared to gold-standard
Panel A of Figure 2 shows box plots of the ratio of the one-sample estimators defined earlier
divided by the gold-standard Aalen-Johansen estimator, separately per treatment arm.
Boxplots for Arm E are slightly different compared to the companion paper, because we use
here τmax as evaluation time. Briefly, incidence proportion and gold-standard often perform
comparably. Probability transforms of the incidence density perform worst when ignoring
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Figure 2: Panel A: Ratios of one-sample estimators per treatment arm. The denominator is
always the gold-standard Aalen-Johansen estimator. Panel B: Ratio of RRs estimated with
estimator of interest and the gold-standard Aalen-Johansen estimator. Panel C: Kernel
density estimates of the RR based on AE probabilities of the estimators divided by the
gold-standard Aalen-Johansen estimator.
CE, but when accounting for CE perform much better than the other three procedures
which are clearly biased with many examples of extreme overestimation. Also, the incidence
proportion displays examples of biases (downwards), with underestimation of up to 67%.
Comparing the two arms, overestimation of the AE probability is more pronounced in Arm
C. These biases become less pronounced when looking at earlier evaluation times which
prevent CEs and censoring after the respective horizon to enter calculations (results not
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shown).
3.4 Meta-analysis for estimators of AE probabilities, per arm
Meta-analyses of all estimators divided by the gold-standard Aalen-Johansen estimator are
displayed in the first two columns of Table 2. These results confirm the visual impression
gathered from the boxplots in Panel A of Figure 2, but we note that Panel A of Figure 2
also displays biases much more pronounced than the meta-analytical averages. In general,
the amount of overestimation increased with later evaluation times (results for earlier
evaluation times not shown). Further investigations included uni- and multivariable meta-
regressions, see the companion paper[1] for Arm E results. Results for Arm C reflect the
different event pattern described above and are consistent (data not shown).
Table 2: Results of the meta-analyses of the log ratio of the estimator of interest divided
by the gold-standard Aalen-Johansen estimator. The first two columns show the estimated
average ratio and 95% CI per treatment arm and meta-analyze the data shown in Panel A of
Figure 2. The third column gives results of the meta-analyses of the response variable log ratio
of the RRs estimated with the estimator of interest and the gold-standard Aalen-Johansen
estimator, the estimated average ratio and 95% CI. The denominator is the RR obtained
using the gold-standard Aalen-Johansen estimator. This third column relates to the Panel B
in Figure 2.
Experimental Control Ratio of RR with 95% CI
Incidence Proportion 0.974 [0.966;0.982] 0.978 [0.970; 0.985] 0.997 [0.991; 1.002]
Probability Transform of the 1.817 [1.733;1.904] 2.424 [2.249; 2.613] 0.732 [0.703; 0.763]
Incidence Density ignoring CE
One minus Kaplan-Meier 1.187 [1.161;1.214] 1.321 [1.257; 1.389] 0.838 [0.786; 0.894]
Probability Transform of the 1.099 [1.080;1.118] 1.124 [1.093; 1.156] 0.977 [0.957; 0.997]
Incidence Density Accounting for CE
Aalen-Johansen (death only) 1.146 [1.125;1.168] 1.254 [1.201; 1.308] 0.860 [0.811; 0.911]
3.5 Estimators of relative AE risk based on probabilities compared to
gold-standard
Panel B in Figure 2 displays boxplots of ratios of RRs estimated with estimator of interest
and the gold-standard Aalen-Johansen estimator. Interestingly, dividing the two biased
estimates of the AE probability based on the incidence proportion, which both tend to
underestimate the true AE probability, leads to an estimate of the RR that on average
performs comparably to the Aalen-Johansen estimator. However, note that compared to
the latter, we see instances with an overestimation of the RR of just short of a factor
3. Performance is comparable for one minus Kaplan-Meier and Aalen-Johansen (death
only): they both overestimate arm-specific AE probabilities but generally underestimate
the RR compared to the gold-standard. This is even more pronounced for the probability
transform of the incidence density ignoring CEs: it overestimates AE probabilities most,
resulting in generally largest underestimation of the RR compared to the gold-standard.
Finally, the probability transform of the incidence density accounting for CEs has a perfor-
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mance comparable to the incidence proportion for estimation of RR. This, in spite of quite
different patterns for estimation of AE probabilities as displayed in Panel A of Figure 2.
Apart from shedding light on estimation quality of individual estimators the latter is a key
conclusion from comparing Panel A and Panel B of Figure 2: different patterns of under-
or overestimation of AE probabilities can lead to similar performance for RR.
This implies that in general, one cannot conclude how an estimator of the relative
AE risk performs based on looking how these same estimators performs on estimation of
arm-wise AE probabilities.
It is interesting to see that the estimators estimating a higher AE probability than the
gold-standard Aalen-Johansen estimator, namely probability transform incidence density
ignoring CEs, one minus Kaplan-Meier, and Aalen-Johansen (death only), yield a smaller
RR compared to the gold-standard. This is because all these estimators do not appro-
priately take into account CEs and overestimate the AE probability the more CEs in an
arm there are. Since we have more CEs in Arm C, this eventually leads to an under-
estimation of the RR. The incidence proportion and the probability transform incidence
density accounting for CEs correctly deal with CEs, leading on average to good estimation
performance of the RR.
As discussed in Stegherr et al.[1] one reason for the good performance of the incidence
proportion might be a high amount of CEs before possible censoring. However, not only
the proportion of censoring but also the timing of the censoring are relevant, as illustrated
in Stegherr et al.
Factors that influence the respective behaviour of a given estimator are discussed below.
3.6 Meta-analyses for estimators of relative AE risk based on probabil-
ities
The third column in Table 2 displays the results of the random-effects meta-analyses for the
log ratio of the two RRs. These are in line with the results discussed above. The average
ratio between the RR calculated with the incidence proportion and RR calculated with
the Aalen-Johansen estimator is close to 1. The biggest underestimation is observed for
the probability transform incidence density ignoring CE, with an average difference of the
risks of about 27%. The Aalen-Johansen (death only) estimator has a more pronounced
underestimation compared to its counterpart accounting for all CE, but this reduction is not
as pronounced as the one using the one minus Kaplan-Meier or the probability transform
of the incidence density ignoring CEs. Finally, the probability transform of the incidence
density accounting for CEs only slightly more underestimates on average compared to
the incidence proportion. In general, these differences decrease when considering earlier
evaluation times (data not shown).
3.7 Uni- and multivariable meta-regressions for estimators of relative
AE risk based on probabilities
For the meta-regressions, we use as covariates the percentage of censoring (for both arms
combined), the percentage of CEs (for both arms combined), the maximum follow-up time,
and the size of the RR as estimated by the gold-standard Aalen-Johansen estimator. Co-
variates were centered, i.e., the row “average RR” contains the average RR of the estimator
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of interest and the Aalen-Johansen estimator if the covariate takes its mean. These means
were 28.6% censoring (= percentage of censored observations until τmax), 53.8% CEs, 2.38
years (781 days) evaluation time, and a RR of 2.55. Table 3 provides results from the uni-
and multivariable analysis.
We illustrate the interpretation of the parameters of the meta regression models by the
following example calculation: The average ratio of the RR calculated with the probability
transform of the incidence density ignoring CEs and the RR calculated with the Aalen-
Johansen estimator at τmax under 28.6% censoring is 0.729. If a trial has 38.6% censoring,
i.e. an increased censoring proportion of 10 percentage points, the average ratio is estimated
as 0.729 · 1.066 = 0.777.
The biggest average underestimation of the RR compared to the gold-standard is seen
for the probability transform of the incidence density ignoring CEs (27 percentage points)
and about the same for one minus Kaplan-Meier and Aalen-Johansen (death only, both
about 16 percentage points). Increasing the censoring proportion compared to their re-
spective mean leads to less underestimation with respect to the gold-standard while the
opposite is true for increasing the proportion of CEs. Increasing the evaluation time or the
size of the gold-standard RR compared to their respective mean has no relevant additional
effect. For the probability transform incidence density accounting for CEs results are on
average comparable to the gold-standard.
These results are confirmed in the multivariable analysis.
In summary, these meta-regressions show that (1) the key difference between estimators
lies in the value of the average RR and (2) the impact of covariates is overall limited,
compared to the average RR the estimated coefficients are close to 1. This emphasizes
that the choice of the estimator is key, and that this holds true over a wide range of
possible data configurations quantified through the considered covariates.
3.8 Variability for estimators of relative AE risk based on probabilities
So far, we have primarily discussed how the different estimators perform compared to the
gold-standard Aalen-Johansen estimator on average. In a first step, variability of the RRs
of every estimator with respect to the gold-standard Aalen-Johansen estimator can be
assessed from the switches between RR categories in Table 1 and the boxplots in Panel B
in Figure 2. Here, we provide a more detailed account of the variability of the RRs using
kernel density estimates of their distribution. As in the one-sample scenario, on average
the incidence proportion appears to provide a good estimator of relative AE risk based on
probabilities. Considering the plot of the kernel density estimates of the RRs of the AE
probability in Panel C of Figure 2, the RR based on the incidence proportion and the gold-
standard is most often close to one. However, there is also a peak of the estimated kernel
density at larger ratios, indicating that the estimators are not always comparable. For the
RR based on the ratio of the probability transform of the incidence density accounting for
CEs and the gold-standard we still have clustering around one, but not as pronounced as
for the incidence proportion. The ratios of the one minus Kaplan-Meier or Aalen-Johansen
(death only) estimator have less values close to one. For these two estimators more values
are smaller than one than larger. The estimated kernel density of the probability transform
of the incidence density ignoring CE has no peak at one but is bimodal with both modes
below one.
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Patterns of frequencies of the AE itself, censoring, and CEs, that may lead to extreme
discrepancies between a given estimator and the gold-standard Aalen-Johansen estimator
for estimation of AE probabilities are discussed in detail in Stegherr et al.[1] Of course,
such extreme configurations in one or both arms may lead to extreme RR estimates also
for the two arm comparison.
3.9 Estimators of relative AE risk based on hazards compared to gold-
standard
Panel A of Figure 3 displays boxplots of the HRs calculated from Cox regression. The three
boxplots display HRs for hazards of AE, all CEs, and a CE of death. Assessing the effect for
the endpoint of interest, here time to AE, as well as of any CE, here time to all CEs or time
to a CE of death, is generally recommended for any (hazard-based) analysis of competing
risks[8]. We find that the hazard of AE is generally larger for Arm E compared to Arm
C, meaning that the instantaneous risk of AE is typically higher, not unexpectedly. For
the hazards of CEs, for both types, what we find is that the hazard in Arm E is generally
lower than in Arm C, i.e. there is an effect of the experimental treatment on the CE. If
we simply censored at CEs we would thus introduce arm-dependent censoring, a feature
that may lead to biased effect estimates[10, 11]. We will use this to explain observations
we make about the conclusions of the RR of the gold-standard Aalen-Johansen estimator
and the HR of the Cox model Table 6 below.
Boxplots of the ratios of incidence density estimates in each arm, evaluated at τE and
τC , respectively, and the gold-standard HR calculated from Cox regression, are provided in
Panel B in Figure 3, for again the same endpoints as in Panel. The ratio of the incidence
densities of the AE in the two arms underestimates with respect to the Cox regression
HR while for the other two endpoints on the median they turn out to be approximately
unbiased compared to the Cox HR, with a tendency to overestimation when accounting
for all CEs and underestimation when only accounting for a CE of death.
To appreciate the differences between the two estimators of the RR based on hazards,
i.e. the incidence density ratio and the gold-standard Cox regression HR, recall the prop-
erties of the two methods: Both properly account for censoring and they properly estimate
event-specific hazards, or rather the relative effect based on these. The only difference
between the two methods is what they assume about the shape of the underlying hazard:
the incidence density assumes them to be constant up to the considered follow-up time,
which also implies that they are proportional. The gold-standard Cox regression HR only
assumes them to be proportional, but not constant. But in addition, we also have different
data patterns for the three event causes for which we show boxplots of relative hazard-
based risks in Panel B in Figure 3: looking at Figure 1 we find a low proportion of events
for AE and an even lower proportion of CEs of death, but a higher proportion of events
for all CEs. Furthermore, within a given patient, death happens later than AE. So the
results we observe in Panel B in Figure 3 are a result of different tradeoffs between all
these aspects.
If we restrict follow-up to earlier timepoints, then variability increases and on average,
results persist for the events of AE and CE of death, but for all CEs the ratio of incidence
densities underestimates with earlier timepoints (data not shown). At earlier timepoints
the number of events for all CEs also decreases, so that the tradeoff with the constant
14
Figure 3: Panel A: Cox regression HRs (on log-scale) for the three event types AE, all CEs,
and CE of death. Panel B: Ratio of RRs estimated with estimator of interest and the gold-
standard HR based on Cox regression estimator, all evaluated at τE and τC . Panel C: Plots
of the kernel density estimates of the HR of the estimators divided by the gold-standard
Cox-regression estimator.
hazard assumption starts to resemble that of an event of AE.
3.10 Meta-analyses for estimators of relative AE risk based on hazards
Table 4 confirms these findings in univariable meta-analyses and provides an average quan-
tification of the amount of underestimation of all three estimators relative to the Cox
15
regression HR.
Table 4: Results of the meta-analyses of the response variable log ratio of the ratio of the
estimator of interest and the HR estimated by the Cox model. Estimated average ratio and
95% CI. The denominator is the HR obtained using the Cox model.
Estimator ratio with 95% CI
Ratio incidence density AE 0.803 [0.741; 0.871]
Ratio incidence density all events CE 0.908 [0.851; 0.969]
Ratio incidence density (death only) CE 0.958 [0.934; 0.982]
3.11 Uni- and multivariable meta-regressions for estimators of relative
AE risk based on hazards
For the meta-regressions reported in Table 5, in line with what has been done for RR in
Table 3, we again use as covariates the percentage of censoring, the percentage of CEs, the
maximum follow-up time, and the size of the HR as estimated by the gold-standard Cox
regression as covariates. Means at which covariates were centered were 29.6% censoring
(= mean percentage of censored observations until τE and τC), 56.7% CEs, 2.72 years (994
days) maximum follow-up time, and a HR of 1.74. Note that these are slightly different
from the ones reported above because we are using a different follow-up time here. In the
univariable analyses in Table 5, we find an estimated average RR below one for time to AE
and time to a CE of death, i.e. a lower average RR compared to the gold-standard Cox
regression estimator, for all covariates. For time to all CEs the ratio of incidence densities
overestimates on average. Most pronounced covariate effects are found for time to AE, for
example the average ratio of the HR based on the incidence density and the gold-standard
Cox regression HR under 29.6% censoring is 0.825. If a trial has 39.6% censoring, i.e.
an increased censoring proportion of 10 percentage points, the estimated average ratio is
estimated as 0.825 · 1.052 = 0.868.
These results are confirmed in the multivariable analysis.
Similar to the estimation of RRs for AE probabilities we find that the effect of covariates
compared to the estimated average HR is rather limited for all three endpoints. This means
again that the choice of estimator, which either allows for an unspecified, freely varying
baseline hazard (Cox) or assumes it to be constant (incidence densities), appears to be
more relevant than the configuration of the data as captured by the covariates.
3.12 Variability in estimation
As for the estimation of RRs based on probabilities, we provide a more detailed account of
the variability of the HRs using kernel density estimates of their distribution. Considering
the plot of the kernel density estimates of the ratios of the HRs in Panel C in Figure 3, the
ratio of the HRs for time to AE has its highest peak just below one, but also further peaks
that are even smaller than one, indicating that the estimators are not always comparable.
The estimated density for the ratio of HRs for time to a CE of death is multimodal, with
the highest peak further below one than for time to AE. A higher proportion of ratios of
HRs for time to all CEs is close to one, but also this estimated density is multimodal. All
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Table 5: Univariable and multivariable meta-regression for the response variable log ratio of the
HRs, estimated with the estimator of interest and the gold-standard Cox regression. The
size of the HR is estimated by the Cox model. Note that for the incidence density of death
only CE the percentage of CEs correspond to the percentage of deaths and for the other two
estimators its the percentage of all events CEs.
incidence density incidence density incidence density
of AE of all events CE of death only CE
Univariable meta-regression
% censoring average HR 0.825 [0.784; 0.868] 1.063 [1.045; 1.081] 0.962 [0.938; 0.986]
10% increase 1.052 [1.031; 1.073] 0.990 [0.983; 0.996] 1.026 [1.015; 1.036]
% CEs average HR 0.786 [0.741; 0.834] 1.061 [1.044; 1.079] 0.942 [0.913; 0.971]
10% increase 0.948 [0.925; 0.971] 1.011 [1.004; 1.017] 1.041 [1.013; 1.071]
size of HR average HR 0.836 [0.790; 0.884] 1.063 [1.048; 1.078] 0.959 [0.932; 0.987]
increase of 0.1 1.004 [1.000; 1.008] 0.972 [0.966; 0.977] 0.996 [0.987; 1.005]
evaluation time average HR 0.854 [0.809; 0.902] 1.053 [1.040; 1.067] 0.976 [0.944; 1.010]
one additional year 0.937 [0.905; 0.970] 0.945 [0.936; 0.955] 0.977 [0.954; 1.000]
Multivariable meta-regression
average HR 0.846 [0.809; 0.884] 1.054 [1.042; 1.066] 1.003 [0.979; 1.029]
% censoring 10% increase 1.058 [1.040; 1.076] 1.004 [0.999; 1.009] 1.038 [1.029; 1.048]
size of HR increase of 0.1 1.005 [1.002; 1.008] 0.980 [0.974; 0.986] 0.993 [0.986; 0.999]
evaluation time one additional year 0.933 [0.907; 0.960] 0.957 [0.948; 0.966] 0.949 [0.931; 0.968]
densities are left-skewed, indicating that there is a relevant portion of AEs for which the
ratio of incidence densities underestimates compared to the gold-standard Cox regression
HR for time to all CEs.
3.13 Impact on RR categories and decisions based on hazard-based rel-
ative AE risk estimates
Table 6 provides a comparison of the conclusions drawn from the estimators of a RR for
time to AE. The majority of AEs either lead to “no effect” or an effect of “major”, and
these are quite consistently detected by the two methods. However, we also observe for
19/94 = 20.2% of AEs a diverging conclusion, following from the combination of bias and
variability in estimation described above.
3.14 Comparison of qualitative decisions on relative effect based on the
two gold-standards
We have considered two effect measures to quantify the RR of an AE in two arms: the RR
based on AE probabilities evaluated at τmax and the HR with maximum available follow-up
in both arms, where Cox’ method of estimating the HR implicitly leads to an evaluation at
τmax, too. Our analyses reveal that all the considered estimators are overall inferior to the
two gold-standards we considered, either the RR based on the arm-wise Aalen-Johansen
estimator or the HR based on Cox regression. One question that remains is whether
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Table 6: Conclusions of the RR calculated with the ratio of incidence densities at τE , τC
and conclusions of the RR calculated with the gold-standard Aalen-Johansen estimator at
τmax compared to the conclusions of the HR calculated with the Cox model at τE , τC . The
table shows the analysis of those n = 94 AEs that were observed with a frequency of ≥ 10
in each arm. Diagonal entries are set in bold face. Off-diagonal zeros are omitted from the
display.
HR Cox for AE
(0) no effect (a) minor (b) considerable (c) major
RR incidence density
(0) no effect 49 1 0 1
(a) minor 3 5 5 0
(b) considerable 2 0 3 1
(c) major 3 0 3 18
RR gold-standard
Aalen-Johansen
(0) no effect 42 3 3 1
(a) minor 9 2 1 0
(b) considerable 4 1 3 2
(c) major 2 0 4 17
the qualitative conclusions drawn based on the two gold-standards are relevantly different
when relying on the criteria put forward by the IQWiG (Table 14 in their general methods
document[9]). Table 6 has the results. We observed quite some different classifications
based on the two estimates of the RR. However, this is not a surprise, as the estimand
the two methods look at is not the same: Cox HR quantifies a relative effect based on an
endpoint of AE hazard, whereas RR based on gold-standard Aalen-Johansen is based on a
comparison of probabilities at a evaluation time. The latter integrates the hazard for the
endpoint of interest and the hazard for CE into one cumulative effect measure, whereas a
Cox regression only considers one hazard at a time, and this is likely the primary reason
for the divergent decisions in the lower part of Table 6. Empirically, if the boxplot for
the HR for the CE in Figure 3 would center around one, then (ignoring the fact that the
categorization also takes into account uncertainty) in theory the decision based on RR and
HR would approximately coincide, i.e. we would have no non-diagonal entries in lower part
of Table 6. But whenever there is an effect on the CE, then it is expected that decisions
diverge.
Summarizing all these analyses concerning effect quantification for AEs using Cox re-
gression based HRs, we conclude that the ratio of incidence densities cannot be considered
a uniformly good approximation of the HR based on Cox regression. We also find that
categorization of the relevance of differences between treatment arms may differ depending
on whether it is based on one event-specific hazard alone (Cox for AE) or on a proper
probability estimator (Aalen-Johansen, integrating the two event-specific hazards).
3.15 Role of Censoring
In this section, we aim to explore how the incidence proportion and one minus Kaplan-
Meier compare in the absence of CEs. To this end, we consider a composite endpoint
where AEs and CEs are combined into one single event. The gold-standard in this setting
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is the one minus Kaplan-Meier estimator which is compared to the incidence proportion
in Figure 4. Since for this endpoint we do not have CEs, the conclusions on relative effects
from the probability- and hazard-based analyses are aligned in the sense of the direction
of the effect.
Figure 4: Ratios of probability estimates (left and middle) and RR (right) based on inci-
dence proportion of the composite endpoint combining AE and CE divided by the corre-
sponding estimate of composite one minus Kaplan-Meier estimator.
As visible in the left and middle boxplot in Figure 4, in the composite endpoint analysis
underestimation by the incidence proportion is more pronounced than in the analysis of
the AE probability presented above. As discussed by Stegherr et al.[1] one reason for
this observation is that even in the presence of censoring, for the one minus Kaplan-Meier
estimator the type of the last event is most important. If the last event is an AE or CE the
one minus Kaplan-Meier estimator is equal to one, even though censoring has been observed
at earlier follow-up times. The incidence proportion is only equal to one if no censoring is
observed. For the RR this leads to an overestimation compared to the gold-standard one
minus Kaplan-Meier estimator.
4 Conclusion
Survival analyses accounting for CEs is methodologically well established, but practical
use lacks behind [12, 13]. Failure to account for censoring (e.g., incidence proportion) or
CEs (e.g., one minus Kaplan-Meier) will generally lead to biased quantification of absolute
AE risk, and the possible amount of bias has been investigated in the companion paper[1].
There, we confirmed that one minus Kaplan-Meier should not be used to estimate the
cumulative AE probability, as it is bound to overestimate as a consequence of ignoring
competing risks. Here, we found that this arm-wise overestimation often leads to an
underestimation of the RR when comparing two arms. The same pattern is observed for
the probability transform incidence density ignoring CE and Aalen-Johansen (death only),
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i.e. the other two estimators that do not correctly account for CEs.
For estimation of AE probabilities, the incidence proportion performed surprisingly well
when compared to the gold-standard Aalen-Johansen estimator. As discussed in Stegherr
et al.[1], the reason was a high amount of CEs before possible censoring, potentially re-
lated to the majority of the seventeen trials analyzed coming from oncology. These good
arm-wise estimates translate in on average unbiased estimation of RR as well. However,
as discussed by Stegherr et al., use of the incidence proportion implicitly assumes events
to be competing as defined in the methods section. Furthermore, although on average the
incidence proportion performs well, we have still 17/156 = 10.9% AE types that were cate-
gorized differently in Table 1, with one being turned from a “major” (incidence proportion)
to a “no effect” with the Aalen-Johansen estimator. Finally, we found that incidence den-
sities, typically criticized because of the restrictive constant hazard assumption, led to the
worst performance when their probability transform ignored CEs. However, accounting
for CEs in an analysis that parametrically mimicked the non-parametric Aalen-Johansen
performed better than both one minus Kaplan-Meier and Aalen-Johansen (death only).
This confirms the conclusion from the one-sample case that ignoring CEs appeared to
be worse than assuming constant hazards in our empirical study. In general, we caution
against making conclusions about the amount and direction of bias for estimation of the
RR based on the behavior of the one-sample estimators. Overall, in terms of relevance
of effects, the choice of the estimator is key and more important than the features of the
underlying data such as percentage of censoring, CEs, amount of follow-up, or the value
of the gold-standard RR.
We focused on the results when evaluating estimators using the maximum follow-up
time as evaluation time. When looking at earlier evaluation times where the estimators
were evaluated at earlier time points defined by quantiles of the observed times (results
not shown in detail), the resulting bias was, in general, less pronounced, due to a reduced
relative frequency of CEs and of censoring (see Figure 1). We regarded the situation of
including all data up to the maximum follow-up time as the most relevant as this is the
usual practice.
Kernel estimates of densities of ratios of estimated RRs by the different estimators
divided by the RR estimated by the gold-standard Aalen-Johansen estimator revealed that
all estimators except probability incidence density ignoring CEs have a peak just below one.
However, all estimators either had further peaks away from one or the estimated density
was unimodal but with high variance. This indicates that the considered estimators are
not always comparable to the gold-standard Aalen-Johansen estimator. In general, it is
not obvious what feature of the data generating mechanism actually leads to observed data
for which, e.g., the incidence proportion performs much worse than the Aalen-Johansen
estimator - we found deviations up to a factor of 3.
Combining bias and variability for estimation of RR for AE probabilities, we analyzed
the impact of using different estimators on making decisions about effect size based on
the criteria put forward by IQWiG. We found that the number of AE types for which a
given estimator deviates from the decision on effect size based on the gold-standard Aalen-
Johansen estimator is non-negligible, and that discrepancies by more than one category
also occur quite often. This is likely a consequence of both, the bias we see for estimation
of RR for some of the estimators and the variability.
The analysis based on hazards reveals that the incidence density underestimates the RR
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for time to AE and time to a CE of death compared to the gold-standard Cox regression,
while no obvious bias was observed for time to all CEs. The discrepancy in conclusions with
regard to effect sizes drawn based on the ratio of incidence densities and the Cox regression
HR appeared to be a bit less than for the estimators of RR based on AE probabilities.
Still, the ratio of incidence densities cannot be considered a uniformly good approximation
of the HR based on Cox regression.
Comparing the evidence categories derived from the two gold-standard estimators, the
Aalen-Johansen estimator of the RR and the Cox regression HR for an AE we find quite
some discrepancies. However, this is not surprising, as the former is based on probability
estimators and as such on cumulative measures integrating the two hazards relating to the
primary event of interest (AE) and the potential CE, whereas the latter is an instantaneous
measure only considering the AE hazard. In other words, this comparison reiterates the
importance of accounting for CEs. There are now as many hazards as there are CEs,
and outcome probabilities depend on all event-specific hazards. We are aware that in
applications it might not be feasible to look at a hazard-based analysis for the AE and
all CEs for every preferred term of AE, say. However, we recommend to consider such an
analysis at least for AEs of special interest.
Finally, in an analysis of a composite endpoint with a single event of AE or CE, we
find an overestimation of RR compared to the gold-standard one minus Kaplan-Meier
estimator.
Our empirical study does have shortcomings, some of which were to be anticipated in
an opportunistic sample of randomized clinical trials. Inter alia, a large number of trials
from oncology came with a high amount of CEs, which, in turn, led to comparable per-
formances of arm comparisons based on incidence proportion and Aalen-Johansen. These
shortcomings have been discussed in detail in the companion paper[1], but this oppor-
tunistic “real world” sample allowed us to investigate and demonstrate which biases can
occur in practice when estimating a RR. The observed results motivate future empirical
investigations on how to quantify RR with the aim of better generalizability. As a further
point, it was not the aim of this investigation to accurately estimate RRs, but to com-
pare different estimators. Our present study does not allow for a meaningful comparison
of results in different diseases. Follow-up investigations concentrating on trials in specific
disease areas are planned.
Methodological restrictions include a focus on AE occurrence in a time-to-first-event
setting, which does not consider recurrent AEs and often excludes AEs after treatment
discontinuation. A more detailed discussion in the companion paper[1] stresses both the
need to consider more complex event histories and the need to still account for CEs in such
considerations. In other words, both AEs after treatment discontinuation and recurrent
AEs will still be subject to CEs, and this must be accounted for when comparing arms.
We focused here on two effect measures, a comparison of probability estimates and the
HR at different evaluation times. This, because we consider these two as the overwhelm-
ingly used effect measures to quantify safety effects and we are interested in assessing
potential biases of those often used methods. Alternative effect measures for time-to-event
endpoints could have been considered as well, a potential candidate being restricted mean
survival time (RMST). However, to the best of our knowledge, RMST is primarily used in
the context of efficacy analyses and also has its challenges, e.g. interpretability and choice
of the restriction timepoint, see the discussion in Freidlin and Korn[14]. Furthermore,
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RMST may be suited for a comprehensive composite endpoint, but extension to CEs is,
although possible, not straightforward.
Replacing the often used incidence proportion by the gold-standard Aalen-Johansen
estimator, while conceptually and empirically indicated, requires careful discussion in trial
teams to define CEs, and a more granular data collection. In addition to the date of AEs
one also needs to collect dates of CEs, which may lead to more missing data, e.g. unknown
date of loss to follow-up.
In line with Stegherr et al.[1], our recommendation is to “play it safe” when estimating
RRs in a time-to-first-event analysis and neither hope for a small amount nor a large
amount of CEs nor a favorable interplay of the distributions of the times of AEs, CEs,
and censorings. In the former case, one minus Kaplan-Meier might work well, while in the
latter two cases the incidence proportion might do so. However, in general the proportion of
CEs cannot exclusively explain how an estimator performs compared to the gold-standard
Aalen-Johansen estimator. Therefore, playing it safe, we recommend using RR based on
the Aalen-Johansen estimator for AE probabilities and the HR from Cox regression for all
types of events that are typically considered in a time-to-first-event analysis. Guidelines for
reporting AEs should therefore advocate the Aalen-Johansen estimator instead of incidence
proportion, incidence density and one minus Kaplan-Meier. A request for results from Cox
regression in guidelines should be complemented by also requesting results for CE-specific
hazards.
Data and code
Individual trial data analyses were run within the sponsor organizations using SAS and R
software provided by the academic project group members. Only aggregated data neces-
sary for meta-analyses were shared and meta-analyses were run centrally at the academic
institutions.
A markdown file providing exemplary code to compute all the estimators discussed in
this paper for a given dataset is available on github: https://github.com/numbersman77/
AEprobs. The corresponding output is available as html file: https://numbersman77.
github.io/AEprobs/SAVVY_AEprobs.html.
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